Chronic arthritis in children and adolescents in two Indian health service user populations by Mauldin, Joyce et al.
BioMed  Central
Page 1 of 7
(page number not for citation purposes)
BMC Musculoskeletal Disorders
Open Access Research article
Chronic arthritis in children and adolescents in two Indian health 
service user populations
Joyce Mauldin1,4, H Dan Cameron2, Diane Jeanotte3, Glenn Solomon1,5 and 
James N Jarvis*1
Address: 1Dept. of Pediatrics, University of Oklahoma College of Medicine, BSEB #235A, Oklahoma City, OK, 73104 USA, 2Oklahoma City Area 
Indian Health Service, Five Corporate Plaza, 3625 NW 56th Street Oklahoma City, OK, 73112 USA, 3Billings Area Indian Health Service, 2900 4th 
Avenue North, Billings, MT 59101 USA, 4Current address: Oklahoma City Area Indian Health Service, Five Corporate Plaza, 3625 NW 56th Street, 
Oklahoma City, OK, 73112 USA and 5Current address: Arthritis & Immunology Program, Oklahoma Medical Research Foundation, Oklahoma 
City, OK, 73104 USA
Email: Joyce Mauldin - jmauldin@ihs.gov; H Dan Cameron - dcameron@ihs.gov; Diane Jeanotte - djeanotte@ihs.gov; Glenn Solomon - glenn-
solomon@ouhsc.edu; James N Jarvis* - james-jarvis@ouhsc.edu
* Corresponding author    
Abstract
Background: High prevalence rates for rheumatoid arthritis, spondyloarthopathies, and systemic
lupus erythematosus have been described in American Indian and Alaskan Native adults. The
impact of these diseases on American Indian children has not been investigated.
Methods: We used International Classification of Diseases-9 (ICD-9) codes to search two Indian
Health Service (IHS) patient registration databases over the years 1998–2000, searching for
individuals 19 years of age or younger with specific ICD-9-specified diagnoses. Crude estimates for
disease prevalence were made based on the number of individuals identified with these diagnoses
within the database.
Results: Rheumatoid arthritis (RA) / juvenile rheumatoid arthritis (JRA) was the most frequent
diagnosis given. The prevalence rate for JRA in the Oklahoma City Area was estimated as 53 per
100,000 individuals at risk, while in the Billings Area, the estimated prevalence was nearly twice
that, at 115 per 100,000. These rates are considerably higher than those reported in the most
recent European studies.
Conclusion:  Chronic arthritis in childhood represents an important, though unrecognized,
chronic health challenge within the American Indian population living in the United States.
Background
As a group, the rheumatic diseases of childhood represent
one of the most common chronic disease conditions in
children [1]. These illnesses have global distribution [2-5],
but little information exists regarding either prevalence or
phenotypic expression of these diseases in children in any
population other than North American and European
whites [6]. Aggarwal and colleagues [7] have reported
their experience with juvenile rheumatoid arthritis (JRA)
on the Indian subcontinent, and their findings suggest
that the patterns of disease reported in Europe and North
America are not seen in that population. Most conspicu-
ous in Aggarwal's study was the relative rarity of the pau-
ciarticular form of JRA, in contrast to European and North
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American populations, where that subtype accounts for
50 to 75% of the cases [3,8-11]. The relative rarity of pau-
ciarticular JRA in non-European populations has been
documented in children of Kuwait [5], Turkey [12], Thai-
land [13], Japan [14] and South Africa [15] as well as in
African American children in Detroit [16]. Further evi-
dence that examining prevalence rates of rheumatic dis-
eases in specific populations may be informative comes
from studies of systemic lupus erythematosus (SLE). Stud-
ies from Great Britain, for example, indicate that the prev-
alence rates for SLE in people of Afro-Caribbean descent
may be 4–8 times higher than that in Caucasians [17,18].
Prevalence rates of rheumatic disease in North American
Indian/First Nations populations have been reported in
small studies from single tribes. From these studies, signif-
icantly higher prevalence rates for rheumatoid arthritis
(RA) have been reported in adults from tribes living in the
Great Lakes region [19], the Pacific Northwest [20], the
Southwest [21] and Canada [22-24].
To our knowledge, a comprehensive survey of rheumatic
diseases affecting children, adolescents, and young adults
has not been reported in any non-Caucasian population.
Because both our clinical experience here in Oklahoma
suggests that rheumatic diseases in children may also be
more prevalent in the American Indian population com-
pared with Caucasians, we undertook a search of the
Oklahoma City Indian Health Service (IHS) user popula-
tion databases in order to develop prevalence estimates of
rheumatic diseases in American Indian children and ado-
lescents. We performed the same queries from the data-
base in the Billings Area IHS office as a basis of
comparison.
Methods
Populations in the billings and Oklahoma City areas
The Oklahoma City Area IHS serves a population of
291,288 individuals, most of whom reside in Oklahoma,
with small numbers living in the neighboring states of
Kansas and Texas [25]. IHS services are limited to mem-
bers of federally recognized tribes, 39 of whom have tribal
headquarters in Oklahoma. The 39 federally recognized
tribes [26] represent people from multiple Native cultures
including Eastern Woodlands tribes (e.g., Cherokee, Del-
aware, Seneca), Southeastern tribes (e.g., Creek, Choctaw,
Chickasaw, Seminole), Southwestern tribes (e.g.,
Apache), as well as tribes who have long been resident on
the southern Great Plains (e.g., Kiowa, Comanche, South-
ern Cheyenne). Tribal membership is determined by the
tribes themselves and may or may not include specific
blood quantum requirements for membership. Historical
factors, the absence of reservations, and the proximity of
European-descended people in Oklahoma has resulted in
significant admixture between Native and Caucasian pop-
ulations in many parts of the Oklahoma City Service Area.
The Billings Area IHS serves a population of 72,591 indi-
viduals. The tribes in this service area, a significant propor-
tion of whom live on 8 reservations located in Montana
and Wyoming, consist largely of northern plains tribes
(e.g., Crow, Sioux, Blackfeet).
In both Areas, the population is younger than the popula-
tion of the United States as a whole, with 40 percent of the
population 19 years of age or younger [27].
Database search
International Classification of Diseases, Ninth Revision,
Clinical Modification (ICD-9) codes were used to search
the Oklahoma City and Billings Area IHS National Patient
Information Reporting Systems and Patient Registration
user databases [28] over a three-year period (1998–2000)
to identify individuals with rheumatic diseases.
Outpatient data over this three-year period was gathered
for the user population ≤ 19 years of age and included:
patient chart number (with the chart number scrambled
to protect patient identity), date of birth, sex, date of visit
and diagnosis (the IHS database allows at least 9 diag-
noses to be recorded on any given patient). The codes
used and the diagnoses denoted by those codes are listed
in Table 1. Data were downloaded into a standard data-
base (Microsoft Excel), which was then searched to elimi-
nate duplicate records and to sort patients for each year on
the basis of age, sex, and diagnosis.
A case was defined as any person who was 19 years of age
or younger on January 1,1998, January 1, 1999 and Janu-
ary 1, 2000 and whose diagnoses included at least one of
the entities listed in Table 1.
The population at risk was defined as the number of indi-
viduals ≤19 years of age within the IHS user population
(i.e., eligible individuals who have used the IHS facilities
at least one time in three years) [29]. The user population
(i.e., people who actually used IHS services) may differ
from the IHS service population, which includes all indi-
viduals who are eligible to receive IHS services. Estimation
of disease prevalence was based on three assumptions: (1)
that the diagnoses recorded were, in fact, accurate; (2) that
the population at risk did not change significantly over
the three-year period; (3) that the three-year mortality rate
for the diseases of interest was no greater in the IHS user
population than for all races in the United States.
For the Oklahoma City Area, accuracy of the IHS database
information was assessed by matching the IHS identifica-
tion number of known JRA cases followed at theBMC Musculoskeletal Disorders 2004, 5:30 http://www.biomedcentral.com/1471-2474/5/30
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Children's Hospital of Oklahoma with the same number
in the IHS patient databank to be sure that known patients
were identified and coded accurately.
Results
Rheumatoid arthritis/juvenile rheumatoid arthritis
Rheumatoid arthritis and juvenile rheumatoid arthritis
(RA/JRA; #ICD-9 # 714.0, 714.30) were the most frequent
rheumatic disease diagnoses recorded in individuals ≤ 19
years of age in both IHS areas. In the Oklahoma City Area,
we identified 62 individuals (45 females and 17 males)
with these diagnoses. Assuming a population at risk of
117,409 (i.e., individuals 19 years of age or younger;
source: IHS Headquarters office, data processing services
unit, Albuquerque, NM), this gives a crude prevalence rate
of 53 cases per 100,000 at risk. The prevalence rate for Bill-
ings was considerably higher. The 714.0 and 714.3 codes
identified 33 individuals in the Billings Area. Based on a
population at risk of 28,724, the prevalence estimate for
Billings was 115 per 100,000 at risk (see Table 2). The age
distribution of affected children, adolescents, and young
adults in both areas differed from what has been reported
in studies from predominantly European or European-
descended populations (Figures 1A and 1B). There is a
distinct biphasic distribution of JRA prevalence by age in
Caucasians, with peaks in the late preschool years and in
early adolescence [30,31]. Data from both IHS databases
show a distinct peak at age 5–12 years with proportion-
ately smaller numbers of patients in the preschool and
early adolescent age groups. In both Areas, peaks in late
adolescence and early adulthood are observed, consistent
with our observation that rheumatoid arthritis is a disease
of young adults in this population (Mauldin et al, manu-
script in preparation). The absence of a prevalence peak in
the preschool years may reflect the almost complete
absence of children with monoarticular or pauciarticular
JRA in the IHS user population, consistent with previous
studies in non-European populations
[5,7,8,13,15,32,33]. We found no individuals in the data-
base with the ICD-9 code commonly used to denote pau-
ciarticular-onset JRA (#ICD-9 # 714.32). In the Oklahoma
City Area we found a single child (a 12 year old female)
diagnosed with monoarthritis (#ICD-9 # 714.33).
Included in the above analyses are individuals who may
not fit established criteria for a diagnosis of JRA. Since we
did not examine age at onset, it is impossible to know
whether a 19 year old identified as having rheumatoid dis-
ease was age 7 or age 17 at disease onset. JRA diagnosis cri-
teria stipulate that patients must have disease onset at 15
years of age or younger [34]. When data were analyzed to
include only children 15 years of age or younger, we iden-
tified 35 patients (23 females, 12 males) in the Oklahoma
City Area and 21 patients in the Billings Area (9 females,
12 males) with a diagnosis of JRA. Based on the popula-
tions at risk of 87,936 (Oklahoma City) and 21,777 (Bill-
ings) this yields an estimated prevalence rate of 40 per
100,000 in the Oklahoma City Area and 96 per 100,000
in the Billings Area. Both of these estimates are more than
twice the prevalence derived from a recent European study
(14.8 per 100,000) [35].
In order to test the integrity of the IHS database in the
Oklahoma City Area, we matched known cases of JRA fol-
lowed at the Children' Hospital of Oklahoma (CHO; n =
15) by IHS identification number with patients in the
database. All 15 of the children followed at CHO were
identified within the database and correctly identified by
subtype.
We did not have access to patient records in the Billings
Area, but do have access to databases at other IHS facili-
ties. At a large facility in the Aberdeen Area (comprising
the states of North Dakota, South Dakota, Nebraska, and
Iowa and serving a patient population very similar to that
served in the Billings Area) we identified 20 children with
JRA using the same search strategy as that used in for the
Billings and Oklahoma City Areas. Subsequent chart
review demonstrated that 17 of these children had strong
clinical evidence to confirm the diagnosis of JRA, while
diagnosis could not be supported or excluded in the other
three. The estimated prevalence for JRA in the population
served by this facility calculates to 236/100,000, within
the same order of magnitude by considerably higher than
the Billings Area estimate.
Table 1: 
ICD-9 CODES Disease
696.0 Psoriatic arthropathy
695.4 Lupus erythematosus (discoid)
710.0 Systemic lupus erythematosus
710.1 Systemic sclerosis
710.2 Sicca syndrome
710.3 Dermatomyositis
710.4 Polymyositis
710.8 Other specified diffuse diseases of connective tissue
710.9 Unspecified connective tissue disease
714.0 Rheumatoid arthritis
Other rheumatoid arthritis of visceral or systemic 
involvement
714.2 Juvenile chronic polyarthritis
714.30 Polyarticular juvenile rheumatoid arthritis, chronic 
or unspecified
714.33 Monoarticular juvenile rheumatoid arthritis
Spondyloarthropathies
720.0 Ankylosing spondylitis
720.1 Spinal enthesopathy
720.2 Sacroilitis, not elsewhere classified
720.8 Other inflammatory spondyloarthopathies
720.89 Other spondyloarthropathiesBMC Musculoskeletal Disorders 2004, 5:30 http://www.biomedcentral.com/1471-2474/5/30
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Spondyloarthropathy
The second most common diagnoses identified in each
Area database were the group of illnesses collectively
denoted spondyloarthropathies (#ICD-9 # 720.0, 720.1,
720.2, 720.8, 720.89). Although these illnesses are some-
times viewed as distinct entities, they share sufficient com-
mon features that allow them to be grouped for purposes
of this analysis. These common features include: (1) male
sex preponderance; (2) arthritic involvement of the axial
skeleton (e.g., sacroiliac joints); (3) extra-articular muscu-
loskeletal involvement (e.g., bursitis, enthesitis); and (4)
extra-articular (e.g., ocular, genito-urinary) inflammation.
In both white [36-38] and American Indian patients [39-
43], the human class I histocompatibility complex anti-
gen HLA-B27 constitutes a strong risk factor [44-47].
We identified 20 patients (12 females, 8 males) with
spondyloarthropathy in the Oklahoma City Area IHS
database, giving an overall crude prevalence rate of 17 per
100,000 at risk. Included in this group are three patients
(all female) with psoriatic arthritis (ICD-9 Code # 696.0).
In the Billings Area, we identified 12 individuals (7
females and 5 males) with ICD-9 codes used to identify
patients with spondyloarthopathy, yielding a prevalence
rate of 42 per 100,000 at risk. These included one patient
(a 12 year old male) with ankylosing spondylitis (#ICD-9
# 720.0), one (a 5 year old male) with psoriatic arthritis
(#ICD-9 #696.0), and 10 patients (6 females and 4 males)
with nonspecific sacroiliitis (#ICD-9 # 720.2). The Okla-
homa and Billings Area estimates were within the range
previously reported for childhood spondyloarthropathies
(e.g. ankylosing spondylitis) in the United States and
United Kingdom (12 to 33 per 100,000) and Mexico (13
to 65 per 100,000) [48], but slightly lower than previously
estimated prevalence rates of 29 per 100,000 (all spondy-
loarthropathies) for First Nations children in western
Canada [22]. The female-to-male preponderance in both
Areas was unusual and has not been, to our knowledge,
reported with any previous population.
Discussion
Although rare individually, the rheumatic diseases, taken
together, are among the most common chronic health
conditions affecting children [1]. Exact prevalence rates
among children living in the United States are difficult to
obtain, owing, in large part, to the de-centralized delivery
of health care in this country. The IHS represents an excep-
tion to that decentralization and is, arguably, the closest
representation to a nationalized health care delivery sys-
tem currently functioning within the United States. Thus,
records and data available through the IHS represent a
unique opportunity to assess population-wide health
needs not otherwise available to child health researchers
in this country. This report provides a first-ever
population-wide estimate of the prevalence of chronic
arthritis in American Indian children living within the
United States. While the prevalence rate for the Oklahoma
City Area was within the same order of magnitude as the
most recent reports from Europe [35], the prevalence rate
in the Billings Area was nearly 10 times this recent Euro-
pean estimate. These findings are consistent with earlier
studies of rheumatoid disease in American Indian adults,
where prevalence rates 10 times higher than the general
population were reported [49,50]. It should be pointed
out, however, that prevalence estimates of JRA vary
widely, ranging between 16 to 113 per 100,000 [30,31,51-
55].
The reasons for the discrepancy in prevalence estimates
between the Oklahoma City and Billings Areas are not
clear. One possibility is that the northern plains tribes are
particularly susceptible to rheumatoid disease in ways
that other groups (e.g., Eastern Woodlands or Southwest-
ern tribes) are not. It is also possible that the difference in
ethnic composition of the two populations accounts for
this difference. While many Oklahoma tribes require at
least a 25% blood quantum of tribal ancestry (e.g., the
Kiowa tribe [56]), other tribes require only proof of
descent from an individual on the original Dawes rolls of
1893 [57]. Thus, the Oklahoma City Area includes many
individuals whose degree of American Indian ancestry is
1/4 or less and may include individuals with less than 1/
64 American Indian ancestry. In contrast, there has been
less intermingling between Caucasian and American
Indian populations on the northern plains, and a larger
Table 2: Rheumatic Diseases in Children and Adolescents Identified in the Oklahoma City and Billings Area Databases
Area Oklahoma City Area Billings
Disease Entity Number Prevalence (Estimated) Number Prevalence (Estimated)
RA/JRA 62 53/100,000 33 115/100,000
Spondyloarthopathy 20 17/100,000 12 42/100,000
SLE 13 11/100,000 4 14/100,000
PMS/DMS 5 4/100,000 4 13/100,000
Other 82BMC Musculoskeletal Disorders 2004, 5:30 http://www.biomedcentral.com/1471-2474/5/30
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percentage of the Billings Area population includes indi-
viduals with full-blooded American Indian ancestry.
Our study once again points out the rarity of the pauci-
articular form of JRA in non-European populations. In
studies of European and European-descended popula-
tions, pauciarticular JRA is the most common form of
chronic childhood arthritis [3,8].
The Oklahoma City Area database listed a single child
with ICD-9 codes #714.32 (pauciarticular JRA) or 714.33
(monoarticular arthritis), the codes used to identify such
children. These findings are consistent with reports from
the Indian subcontinent,[7] Kuwait [5], Turkey [12], Thai-
land [13], Japan [14], South Africa [15], and with our
experience with African American children in Detroit [16].
Bar graphs showing the age and sex distributions of children with JRA identified in the Oklahoma City Area (A) and Billings  Area (B) IHS databases Figure 1
Bar graphs showing the age and sex distributions of children with JRA identified in the Oklahoma City Area (A) and Billings 
Area (B) IHS databases. In each Area, there was a conspicuous under-representation of both pre-school children and early 
adolescents diagnosed with JRA.BMC Musculoskeletal Disorders 2004, 5:30 http://www.biomedcentral.com/1471-2474/5/30
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The slight female-to-male preponderance for spondy-
loarthopathy is also worth noting. High prevalence rates
for spondyloarthopathies have been noted in both North-
western and Southwestern tribes [24,41-44]. However, in
these studies, a strong male preponderance was noted.
Whether the findings from Oklahoma City and Billings
represent a novel finding or inaccuracies in the ICD-9 cod-
ing await confirmatory studies, as we discuss below.
An important limitation to this study is the fact that we
did not have the means to verify every individual case
listed in Oklahoma City database and were unable to con-
firm any diagnosis in the Billings Area database. However,
our limited test of the accuracy of the Oklahoma City data
provided surprising confirmation of the accuracy of cod-
ing for known cases. While we could not confirm any of
the Billings cases, our search of the database of a single
IHS facility in the neighboring Aberdeen Area corrobo-
rated the prevalence statistics we derived from the Okla-
homa City and Aberdeen databases. Indeed, our
experience suggests that a search strategy like the one we
used is likely to under-estimate rather than over-estimate
the prevalence of rheumatic disease in the IHS user
population.
We are aware that there are many factors that might over-
estimate disease prevalence using this type of database
search. The first is the possibility that a given ICD-9 code
might have been used to designate a "working" diagnosis
that was never established by the patient's clinical course.
The second opportunity for overestimation of prevalence
would occur if children were systematically misdiag-
nosed. This could occur easily if physicians use serologic
data as the sole criterion for diagnosis. For example, many
physicians routinely screen children with musculoskeletal
complaints using antinuclear antibody (ANA) tests. How-
ever, the prevalence of low-titer positive ANA tests is
extraordinarily high in the pediatric population [58].
Thus, if ANA-positive children with musculoskeletal pain
[59] are listed as having "JRA," then there would be a gross
overestimation of the actual prevalence.
Similarly, there are factors that might have led to underes-
timation of JRA prevalence by relying solely on a three-
year database search. Children or adolescents with well-
controlled JRA may not have seen an IHS physician during
the relevant time period, and thus would have been
excluded. Similarly, physicians who rely on rheumatoid
factor tests as a diagnostic criterion for JRA might fail to
diagnose the disease in a child, since only a small number
of children with JRA have detectable IgM rheumatoid fac-
tor [60].
The ideal method for obtaining true disease prevalence
rates would include rigorous, pro-active case finding in a
known population at risk. This approach was taken by
Manners and Diepeveen in a study of school children in
Australia [61]. Using such an approach, these authors
reported a prevalence rate of 4 per 1,000 for JRA, signifi-
cantly higher than any previous estimates. We are now
preparing a similar project involving American Indian
communities on the northern plains.
Conclusion
We conclude that the rheumatic diseases of childhood
may represent a significant burden of morbidity in these
two IHS user populations. More detailed studies with
rigorous case ascertainment are required to follow up
these preliminary data.
Competing Interests
None declared.
Authors' Contributions
Dan Cameron provided data from the IHS database in
Oklahoma City, and Diane Jeannotte provided the Bill-
ings Area data. Joyce Mauldin and Glenn Solomon per-
formed the database searches. Dr. Jarvis directed this
study and assisted in data analysis and interpretation.
Acknowledgements
This work was supported by a generous grant from the Arthritis Founda-
tion (to JNJ). The authors would like to extend special thanks to Dr.'s Ever-
ett R. Rhoades and David Grossman for their review and thoughtful 
comments on this manuscript. The authors would also like to thank Julie 
McGhee for proofreading and suggestions for this manuscript.
References
1. Petty RE, Cassidy JT: Introduction to the study of rheumatic
diseases in children. In Textbook of Pediatric Rheumatology Edited by:
Cassidy JT, Petty RE. Philadelphia: WB Saunders Co; 2001:5. 
2. Aggarwal A, Misar R: Juvenile chronic arthritis in India: is it dif-
ferent from that seen in Western countries?  Rheumatol Int
1994, 14:53-56.
3. Oen KG, Cheang M: Epidemiology of chronic arthritis in
childhood. Semin Arthritis Rheum 1996, 26:575-591.
4. Pagan TM, Arroyo IL: Juvenile rheumatoid arthritis in Carib-
bean children: a clinical characterization.  Boletin Assoc Med
Puerto Rico 1991, 83:527-529.
5. Kuffash FA, Majeed HA, Lubani MMl: Epidemiology of juvenile
chronic arthritis and other connective tissue diseases among
children in Kuwait. Ann Trop Paediatr 1990, 10:255-259.
6. Gare BA: Arthritis – who gets it, where and when? A review
of current data on incidence and prevalence. Clin Exp Rheumatol
1999, 17:367-374.
7. Aggarwal A, Misra RN: Juvenile rheumatoid arthritis in India:
rarity of antinuclear antibody and uveitis. Indian J Pediatr 1996,
63:301-304.
8. Oen K: Comparative epidemiology of the rheumatic diseases
in children. Curr Opin Rheumatol 2000, 12:410-414.
9. Sathananthan R, David J: The adolescent with rheumatic
disease. Arch Dis Child 1997, 7:355-358.
10. Aaron S, Fraser PA, Jackson JM, Larson M, Glass DN: Sex ratio and
sibship in juvenile rheumatoid arthritis kindreds.  Arthritis
Rheum 1985, 28:753-758.
11. Glass DN, Giannini EH: Juvenile rheumatoid arthritis as a com-
plex genetic trait. Arthritis Rheum 1999, 42:2261-2268.
12. Ozdogan H, Kasapcopur O, Dede H, Arisoy N, Beceren T, Yurdakul
S, Yazici H.: Juvenile chronic arthritis in a Turkish population.
Clin Exp Rheum 1991, 9:431-435.BMC Musculoskeletal Disorders 2004, 5:30 http://www.biomedcentral.com/1471-2474/5/30
Page 7 of 7
(page number not for citation purposes)
13. Pongpanich B, Daengroongroj P: Juvenile rheumatoid arthritis:
clinical characteristics in 100 Thai patients.  Clin Rheumatol
1988, 7:257-261.
14. Kobayashi T, Tanaka S, Maeda M, Okubo H, Matsuyama T, Watanabe
N: A study of prognosis in 52 cases with juvenile rheumatoid
arthritis. Acta Paediatr Jap 1993, 35:439-446.
15. Haffejee IE, Raga J, Coovadia HM: Juvenile chronic arthritis in
Black and Indian South African children. South African Med J
1984, 65:510-514.
16. Schwartz MM, Simpson P, Kerr KL, Jarvis JN: Juvenile rheumatoid
arthritis in African Americans. J Rheumatol 1997, 24:1826-1829.
17. Molokhia M, McKeigue PM, Cuadrado M, Hughes G: Systemic lupus
erythematosus in migrants from west Africa compared with
Afro-Caribbean people in the UK. Lancet 2001, 357:1414-1415.
18. Johnson AE, Gordon C, Palmer RG, Bacon PA: The prevalence and
incidence of systemic lupus erythematosus in Birmingham,
England. Arthritis Rheum 1995, 38:551-558.
19. Harvey J, Lotze M, Stevens MB, Lambert G, Jacobson D: Rheuma-
toid arthritis in a Chippewa Band. I. Pilot screening study of
disease prevalence. Arthritis Rheum 1981, 24:717-721.
20. Willkens RF, Hansen JA, Malmgren JA, Nisperos B, Mickelson EM,
Watson MA: HLA antigens in Yakima Indians with rheuma-
toid arthritis. Lack of association with HLA-Dw4 and HLA-
DR4. Arthritis Rheum 1982, 25:1435-1439.
21. Del Puente A, Knowler WC, Pettit DJ, Bennett PH: High incidence
and prevalence of rheumatoid arthritis in Pima Indians. Am J
Epidemiol 1989, 129:1170-1178.
22. Rosenberg AM, Petty RE, Oen KG, Schroeder ML: Rheumatic dis-
eases in Western Canadian Indian children. J Rheumatol 1982,
9:589-592.
23. Oen K, Schroeder M, Jacobson K, Anderson S, Wood S, Cheang M,
Dooley J: Juvenile rheumatoid arthritis in a Canadian First
Nations (aboriginal) population: onset subtypes and HLA
associations. J Rheumatol 1998, 25:783-790.
24. Hill RH, Robinson HS: Rheumatoid arthritis and ankylosing
spondylitis in British Columbia Indians: their prevalence and
the challenge of management.  Canad Med Assoc J 1969,
100:509-511.
25. Rhoades ER, Deer Smith MH: Health care of Oklahoma Indians.
J Ok St Med Assoc 1996, 89:165-172.
26. Oklahoma Indian Affairs Commission: Tribal Enrollment Figures 2002.
27. Trends in Indian Health. U.S. Dept of Health and Human Services
1996:31-32.
28. U.S. Department of Health and Human Services Indian Health Service:
Final User Population Estimates – FY. 2001.
29. Indian Health Service: Indian Health Service Regional Differences in
Health, US Dept of Health and Human Services 1994:12.
30. Sullivan DB, Cassidy JT, Petty RE: Pathogenic implications of age
of onset of juvenile rheumatoid arthritis. Arthritis Rheum 1975,
18:251-255.
31. Towner SR, Michet CJ Jr, O'Fallon WM, Nelson AM: The epidemi-
ology of juvenile arthritis in Rochester, Minnesota 1960–
1979. Arthritis Rheum 1983, 26:1208-1213.
32. Khuffash FA, Majeed HA: Juvenile rheumatoid arthritis among
Arab children. Scand J Rheum 1988, 17:393-395.
33. Kanyerezi BR, Mbidde E: Juvenile chronic polyarthritis in Ugan-
dan African children. East Africa Med J 1980, 57:484-489.
34. von Koskull S, Truckenbrodt H, Holle R, Hormann A: Incidence and
prevalence of juvenile arthritis in an urban population of
southern Germany: a prospective study. Ann Rheum Dis 2001,
60:940-945.
35. Brown MA, Pile KD, Kennedy LG, Calin A, Darke C, Bell J, Words-
worth BP, Cornelis F: HLA class I associations of ankylosing
spondylitis in the white population in the United Kingdom.
Ann Rheum Dis 1996, 55:268-270.
36. Ansell BM, Bywaters EG, Lawrence JS: Familial aggregation and
twin studies in Still's disease. Juvenile chronic polyarthritis.
Rheumatol 1969, 2:37-61.
37. van der Linden SM, Valkenburg HA, deJongh BM, Cats A: The risk of
developing ankylosing spondylitis in HLA-B-27 positive indi-
viduals. A comparison of relative of spondylitis patients with
the general population. Arthritis Rheum 1984, 27:241-249.
38. Khan MA: Spondyloarthropathies in non-Caucasian popula-
tions of the world. In: Advances in inflammation research Volume 9.
Edited by: Ziff M, Cohen SB. The spondyloarthropathies. New York:
Raven Press; 1985:91-99. 
39. Boyer GS, Templin DW, Cornoni-Huntley JC, Everett DF, Lawrence
RC, Heyse SF, Miller MM, Goring WP: Prevalence of spondyloar-
thropathies in Alaskan Eskimos.  J Rheumatol 1994,
21:2292-2297.
40. Gofton JP, Chalmers A, Price GE, Reeve CE: HLA B27 and anky-
losinog spondylitis in B.C. Indians. J Rheumatol 1984, 11:572-573.
41. Calin A, Bennett PH, Jupiter J, Terasaki PI: HLA B27 and sacroilitis
in Pima Indians-association in males only. J Rheumatol 1977,
3(suppl):45-48.
42. Morse HG, Rage RG, Bonnell MD, Kuberski T: High frequency of
HLA-B27 and Reiter's syndr o m e  i n  N a v a j o  I n d i a n s .   J
Rheumatol 1980, 7:900-902.
43. Lee YE, Choi SJ, Yoon SY, Lee KN, Ji JD, Song GG: Quantitative
analysis of HLA-B27 by flow cytometry using CD3 gating in
seronegtive spondylarthropathies.  Clin Exp Rheumatol 1999,
17:191-195.
44. Braun J, Bollow M, Remlinger G, Eggens U, Rudwaleit M, Distler A,
Sieper J: Prevalence of spondyloarthropathies in HLA-B27
positive and negative blood donors.  Arthritis Rheum 1998,
41:58-67.
45. Hoyle E, Laval SH, Calin A, Wordsworth BP, Brown MA: The x-
chromosome and susceptibility to ankylosing spondylitis.
Arthritis Rheum 2000, 43:1353-1355.
46. Burgos-Vargas R, Vazquez-Mellado J: The early clinical recogni-
tion of juvenile-onset ankylosing spondylitis and its differen-
tiation from juvenile arthritis. Arthritis Rheum 1995, 38:835-844.
47. Burgos-Vargas R, Petty RE: Juvenile ankylosing spondylitis. Rheum
Dis Clin North Am 1992, 18:123-142.
48. Beasley RP, Willkens RF, Bennett PH: High prevalence of rheuma-
toid in Yakima Indians. Arthritis Rheum 1973, 16:743-748.
49. Harvey J, Lotze M, Arnett FC, Bias WB, Billingsley LM, Harvey E, Hsu
SH, Sutton JD, Zizic TM, Stevens MB: Rheumatoid arthritis in a
Chippewa band. II. Field study with clinical serologic and
HLA-D correlations. J Rheumatol 1983, 10:28-32.
50. Gewanter HL, Roghmann KJ, Baum J: The prevalence of juvenile
arthritis. Arthritis Rheum 1983, 26:599-603.
51. Oen K, Fast M, Postl B: Epidemiology of juvenile rheumatoid
arthritis in Manitoba, Canada. 1975–92: Cycles in incidence.
J Rheumatol 1995, 22:745-750.
52. Rosenberg AM: Analysis of a pediatric rheumatology clinic
population. J Rheumatol 1990, 17:827-830.
53. Malleson PN, Fung MY, Rosenbert AM: The incidence of pediatric
rheumatic diseases: results from the Canadian Pediatric
Rheumatology Association Disease Registry. J Rheumatol 1996,
23:1981-1987.
54. Peterson LS, Mason T, Nelson AM, O'Fallon WM, Gabriel SE: Juve-
nile rheumatoid arthritis in Rochester, Minnesota 1960–
1993. Is the epidemiology changing?  Arthritis Rheum 1996,
39:1385-1390.
55. Kiowa Tribal Constitution: Article 2. Sect 1B (Tribal
membership). .
56. Champagne D: Native America: Portrait of the Peoples Detroit, Visible
Ink Press; 1994:253-254. 
57. Malleson PN, Sailer M, Mackinnon MJ: Usefulness of antinuclear
antibody testing to screen for rheumatic diseases. Arch Dis
Child 1997, 77:299-304.
58. McGhee JL, Burks FN, Sheckels JN, Jarvis JN: Identifying children
with chronic arthritis based on chief complaints. Absence of
musculoskeletal pain as a predictor of chronic arthritis in
children. Pediatrics 2002, 110:354-359.
59. Eichenfield AH, Athreya BH, Doughty RA, Cebul RD: Utility of
rheumatoid factor in the diagnosis of juvenile rheumatoid
arthritis. Pediatrics 1985, 78:480-484.
60. Manners PJ, Diepeveen DA: Prevalence of juvenile chronic
arthritis in a population of 12 year old children in urban
Australia. Pediatrics 1996, 98:84-90.
Pre-publication history
The pre-publication history for this paper can be accessed
here:
http://www.biomedcentral.com/1471-2474/5/30/prepub